Bupropion SR |
Budeprion SR; Wellbutrin SR |
Clinical Trial: Effect of Combined Pharmacotherapy/Behavioral Treatment on Smoking Cessation For Methadone Maintenance Therapy Patients - 2
This study is no longer recruiting patients.
Purpose
The purpose of this pilot study is to examine the effects of combined pharmacotherapy (Zyban/NRT)/behavioral treatment on smoking cessation among methadone maintenance therapy patients.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Tobacco Use Disorder | Behavior: Bupropion | Phase II |
MedlinePlus related topics: Smoking
Study Type: Interventional
Study Design: Treatment, Active Control
Official Title: Pilot study examining the effects of combined pharmacotherapy (Zyban/NRT)/behavioral treatment on smoking cessation among MMT patients.
Expected Total Enrollment: 34
Study start: September 2002; Study completion: September 2003
This is a one-arm, open label pilot study of MMT patients to determine whether bupropion, nicotine replacement therapy, and behavioral counseling is a feasible and potentially effective intervention for smoking cessation. The smoking behaviors of participants will be be followed for 6 months post quit-date to determine effect-size estimates for a future, large scale trial.
Eligibility
Ages Eligible for Study: 18 Years - 70 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Patients in long-term methadone maintenance treatment
- Patient smokes at least 10 cigarettes per day, are stable on their use of methadone (phase 2 or higher treatment), smoked for at least 1 year, be willing to participate for 6 months, and not have used bupropion or nicotine replacement therapy for 6 months
Exclusion Criteria:
- Patients who use prescription drug regimens that might affect methadone or bupropion metabolism
- Patients with cardiovascular disease, asthma, COPD
- Patients who are pregnant or breastfeeding
- Patients with regular use of alcohol, other illicit drugs, or other types of tobacco (chewing or pipe for example)
Location Information
Kansas
University of Kansas Medical Center, Kansas City, Kansas, 66160 7420, United States
Kimber Richter, Ph.D., Principal Investigator, University of Kansas
More Information
Record last reviewed: June 2004
Last Updated: February 16, 2005
Record first received: May 14, 2003
ClinicalTrials.gov Identifier: NCT00060814
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Not Signed In -


